Holen Sie sich die Stockscreener-App
36.18
1.83%
0.65
Smith Nephew Plc Adr Aktie (SNN) Neueste Nachrichten
Anti-Biofilm Agents Market to Worth Over USD 4.32 Billion By 2035 | Escalating Hospital Infection Rates Drive Urgent Clinical Agent Adoption and Market Growth says Astute Analytica - GlobeNewswire Inc.
Jim Cramer on Smith & Nephew: "This Group, I Do Not Like" - Finviz
Smith+Nephew completes acquisition of Integrity Orthopaedics; establishes unrivalled portfolio for shoulder repair - Finviz
The Truth About Smith & Nephew plc: Why This ‘Boring’ Med-Tech Stock Might Be Your Sneaky Power - AD HOC NEWS
Smith & Nephew ADR trying to close in on key technical benchmark - MSN
The Truth About Smith & Nephew plc (ADR): Wall Street Sleeper Stock or Total Snooze? - AD HOC NEWS
Smith & Nephew plc (ADR): Quiet Charts, Cautious Optimism – Is SNN a Sleeper in Medtech? - AD HOC NEWS
Smith & Nephew (SN, SNN) Stock Outlook for December 2025: Q3 Setback, $500m Buyback and What Comes Next - ts2.tech
Smith and Nephew (LON:SN) positioned across FTSE 100 Today healthcare landscape - Kalkine Media
FTSE 100 today: Pound lower; Magnum debuts, Smith & Nephew sets new goals - Investing.com
Smith & Nephew Unveils RISE Blueprint for a Stronger Future - Kalkine Media
Smith+Nephew sets ambitious growth targets through 2028 - Investing.com
Smith & Nephew (SNN) Stock Forecast 2026: Q3 2025 Results, $500m Buyback and New Board Signals - TechStock²
Smith & Nephew PLC (NYSE:SNN): A Value Investment in Medical Devices - Chartmill
[6-K] SMITH & NEPHEW PLC Current Report (Foreign Issuer) | SNN SEC FilingForm 6-K - Stock Titan
Smith & Nephew PlcDirector/PDMR Shareholding - Research Tree
REGSmith & Nephew PlcDirector/PDMR Shareholding - TradingView
Smith & Nephew stock initiated with Buy rating at Kepler Cheuvreux - Investing.com
Shell Stock Price Today (12 Nov 2025): SHEL ADR edges lower as oil slides; London closes at 2,909p amid fresh buyback and Volta Media sale - ts2.tech
Smith+Nephew shares tumble as Q3 sales miss expectations - Investing.com
Analysts Set Smith & Nephew SNATS, Inc. (NYSE:SNN) Price Target at $36.75 - Defense World
Smith+Nephew comparative study1 shows PICO◊ sNPWT (-80 mmHg) delivers superior performance in relation to wound dehiscence and reduces healthcare costs across cardiovascular and orthopedic surgery versus PrevenaTM -125 mmHg sNPWT - Sahm
Predictions - sharewise.com
UFC® and Smith+Nephew announce multi-year extension of partnership - The Globe and Mail
Smith & Nephew stock price target raised to GBP17 by RBC on growth outlook - Investing.com Australia
Smith & Nephew schedules third quarter trading report release for November 6 - Investing.com
BlackRock Adjusts Voting Rights in Smith & Nephew - The Globe and Mail
Smith & Nephew stock rating downgraded by Bernstein as valuation recovers - Investing.com
Smith+Nephew announces new category I CPT® code for its CARTIHEAL™ AGILI-C™ Cartilage Repair Implant - Sahm
Smith+Nephew announce latest scientific data supporting new ALLEVYN™ COMPLETE CARE 5-Layer Foam Dressing for pressure injury prevention - Sahm
Smith & Nephew’s ratings affirmed by Moody’s with positive outlook - Investing.com
Smith+Nephew launches CORIOGRAPH™ Pre-Op Planning and Modeling Services for total shoulder arthroplasty - The Globe and Mail
Park Avenue Securities LLC Acquires 583 Shares of Smith & Nephew SNATS, Inc. $SNN - Defense World
Smith & Nephew CFO John Rogers relocates to US, receives revised compensation - Investing.com
Citi Keeps Their Hold Rating on Koninklijke Philips N.V. (0LNG) - The Globe and Mail
1.33%
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):